Plasticizers like di(2-ethylhexyl) phthalate (DEHP) have been used to increase the elasticity, transparency, durability and stability of the polyvinyl chloride used for blood bags and tubing for five decades.
1 DEHP can leach from the polyvinyl chloride, and its toxicity is an issue of concern.
2 There have been reports that DEHP, and its derivative mono(2-ethylhexyl) phthalate (MEHP), could disrupt the endocrine system. 3 Although agreement on the effect of DEHP on human health has not been reached, recommendations have been made to avoid exposing some sensitive populations to it, such as pregnant women who are carrying male fetuses, male neonates and peripubertal males. 4 In our cord blood bank procedures, we routinely use DMSO, which is known as a solvent, for cryopreservation. Although the final concentration of DMSO is commonly between 5 and 10%, v/v, it is much higher when the cryoprotectant goes through tubing. The DMSO may cause the plasticizer to be released into the cell component.
Below we report the levels of DEHP measured in our frozen cord blood units. Our cord blood bank has been operated by the same research and technical team as a part of the Japanese Red Cross (JRC) blood center in Tokyo since 1995.
The cord blood was collected into a 200 mL collection bag containing 28 mL of citrate-phosphate-dextrose (Kawasumi, Tokyo, Japan), transferred to our facility and processed within 24 h. The processing of one unit involved the use of a 150 mL separation bag (Kawasumi), a bag connector made with acrylonitrile butadiene styrene (Terumo, Tokyo, Japan), syringes (Terumo), a winged needle set (Nipro, Osaka, Japan) and a freezing bag (F-025A, Nipro). The collection and separation bags were made of polyvinyl chloride with DEHP. The freezing bag was made of high-molecular-weight polyethylene and was DEHP free.
We used hydroxyethyl starch (HES40, Nipro) to sediment the RBCs, and the final DMSO concentration was 10%. Prior to 2008, we used Cryoserv (Nipro) and 10% Dextran40 (DextseranD40, Terumo) to prepare the cryoprotectant of 50% DMSO/5% Dextran40, and since 2008 we have used a 55%, w/v, DMSO/5% Dextran40 mixture (CryoSure-DEX40, WAK-Chemie, Steinbach, Germany).
We divided our processing procedures into three periods: (1) before 2008, when we used one syringe for each of the DMSO and the 10% Dextran40, and then mixed them together using a three-way stopcock of polycarbonate (Terumo) before adding the mixture to our cell fraction; (2) from 2008 to 2012, during which the original collection bag was used through to the end of the processing; and (3) since the start of 2012, when we began collecting the buffy coat fraction into a separation bag to process further. At this time the winged needle set, through which the 50% DMSO is added to the cell suspension, was changed to become a DEHP-free product.
The exact test with a ¼ 0.05 and power ¼ 0.8, gave 27 as the total sample size necessary, using SAS (ver. 9.1.3, SAS Institute Inc., Cary, NC, USA). Therefore, for each of the three periods we chose nine cord blood units for the DEHP measurements.
A cord blood sample of 1 mL was mixed with 2 mL of acetonitrile in a glass tube. After centrifugation (5 min at 600 g), the supernatant was filtered. A HPLC was performed with an Alliance system 2695, 2998 PDA detector (Waters, Milford, MA, USA) and an Atlantis dC18 column (4.6 mm Â 150 mm, 5 mm), at a flow rate of 1 mL/min. A sample of 10 mL was injected into the column at 40 1C. The eluent was monitored at 273 nm. Separations were performed with a mobile phase consisting of 1% acetic acid/acetonitrile mixture; 50% acetonitrile for the first 3 min and 100% acetonitrile after. MEHP and DEHP elucidate at 6.7 and 8.8 min, respectively. The DEHP (DOP standard, Wako Pure Chemical, Osaka, Japan) and MEHP (Wako Pure Chemical) were used as controls. The glassware was washed with acetone beforehand.
We determined the background level of DEHP in our procedures by keeping PBS instead of cord blood with 10% DMSO in the separation and freezing bags for 10 and for 20 min. The 10% DMSO/PBS in the separation bags contained an average of 1.7 mg/L of DEHP and in the freezing bags contained an average of 1.2 mg/L of DEHP, with no detection of MEHP.
Before processing and within 24 h from the time of collection, the cord blood contained 17.8±2.7 mg/L of DEHP and
When standard DEHP and MEHP was added to the cord blood, the average recovery was 108.8% and 94.4%, respectively.
For the samples from the three periods, measurements were carried out twice, with the results shown in Figures 1 and 2 . There were no differences in the DEHP and MEHP levels among the three periods by one-way analysis of variance analysis. As there were 17.8 mg/L of DEHP and 1.0 mg/L of MEHP in the cord blood at the start, with an average volume of 91.7 mL, and 16.5 mg/L of DEHP and 1.1 mg/L of MEHP in the final product of 25 mL, we can assume that the majority of the phthalates are carried over from when the cord blood was in the collection bag.
The irradiated RBC concentrates of the JRC, 20 days from collection, have been reported to contain up to 36 mg/L of DEHP and 3.3 mg/L of MEHP. 5 The total amount of phthalates in one unit of cord blood (25 mL), 0.4 mg of DEHP and 0.03 mg of MEHP in average, is less than that of one bag of blood for transfusion. Assuming that one (2) and (3) (n ¼ 9 for each) and for the total 27 samples were 17.2±4.2, 15.3±2.0, 17.2±2.5 and 16.5 ± 3.1, respectively. unit of cord blood, 25 mL, of the highest DEHP concentration is used for a baby of 3 kg, we can calculate that the recipient would receive 0.19 mg/kg of DEHP, which is lower than the parental tolerable intake value. 6 As the toxicity of MEHP has also been reported, 7 for sensitive populations the intake of phthalates should be a consideration.
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